The Lantern is billed as an AI platform aimed at accelerating revenue workflows, claiming 41% better forecast accuracy and automated outreach. The Champion Agent monitors personnel shifts across the customer base to automate outreach for certain teams. In pharma, Lantern Pharma reports 2026 progress, reducing R&D spend by 47% while advancing multiple clinical programs, launching a multi-agent AI platform with Zeta.ai and expanding an AI Center of Excellence in India to scale RADR. These developments illustrate Lantern's growth into AI-driven sales intelligence, with ongoing financing activities to support growth.
Disciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million Q1 net loss reduced 27% year-over-year while progressing multiple...
www.pharmiweb.comlantern News and Updates from The Economictimes.com
economictimes.indiatimes.comnews
www.newswire.caBrowse, deploy, and customize AI agents that automate every critical revenue function—from champion tracking to intent monitoring, all available in minutes.
withlantern.comLantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform...
www.innovationopenlab.comDisciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million
natlawreview.com